Listen
HUMIRA
-
Opinions on drugs -
Posted on
May 05 2010
- Updated on
May 17 2011
Reason for request
Renewal of inclusion on the list of medicines reimbursed by National Health Insurance (+ request for reassessment of the wording of the improvement in actual benefit (IAB) in psoriasis, following the submission of new data).
-
Clinical Benefit
| Substantial |
The actual benefit provided by HUMIRA remains substantial for all its indications. |
Clinical Added Value
| no clinical added value |
The nature of these new data cannot change the IAB assigned to HUMIRA in the treatment for psoriasis (no IAB compared to other anti-TNF alpha agents) in previous opinion of the Transparency committee. |
Contact Us
Évaluation des médicaments
